Novel brain-targeted nanomicelles for anti-glioma therapy mediated by the ApoE-enriched protein corona in vivo
The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regar...
Saved in:
| Published in | Journal of nanobiotechnology Vol. 19; no. 1; pp. 453 - 24 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
28.12.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle‒protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid β-protein (Aβ)-CN peptide (PTX/Aβ-CN-PMs). Aβ-CN peptide, like the Aβ
peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding Aβ-CN-PMs (ApoE/PTX/Aβ-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood-brain barrier and glioma, effectively mediating brain-targeted delivery.
PTX/Aβ-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC-MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/Aβ-CN-PMs were also well studied.
The average size and zeta potential of PTX/Aβ-CN-PMs and ApoE/PTX/Aβ-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/Aβ-CN-PMs, and the PTX release from rhApoE/PTX/Aβ-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of Aβ-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood-brain tumor barrier in vitro. Meanwhile, PTX/Aβ-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/Aβ-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona.
The designed PTX/Aβ-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. |
|---|---|
| AbstractList | The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle‒protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid β-protein (Aβ)-CN peptide (PTX/Aβ-CN-PMs). Aβ-CN peptide, like the Aβ
peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding Aβ-CN-PMs (ApoE/PTX/Aβ-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood-brain barrier and glioma, effectively mediating brain-targeted delivery.
PTX/Aβ-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC-MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/Aβ-CN-PMs were also well studied.
The average size and zeta potential of PTX/Aβ-CN-PMs and ApoE/PTX/Aβ-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/Aβ-CN-PMs, and the PTX release from rhApoE/PTX/Aβ-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of Aβ-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood-brain tumor barrier in vitro. Meanwhile, PTX/Aβ-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/Aβ-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona.
The designed PTX/Aβ-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. Background The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle-protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid [beta]-protein (A[beta])-CN peptide (PTX/A[beta]-CN-PMs). A[beta]-CN peptide, like the A[beta].sub.1-42 peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding A[beta]-CN-PMs (ApoE/PTX/A[beta]-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood-brain barrier and glioma, effectively mediating brain-targeted delivery. Methods PTX/A[beta]-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC-MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/A[beta]-CN-PMs were also well studied. Results The average size and zeta potential of PTX/A[beta]-CN-PMs and ApoE/PTX/A[beta]-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/A[beta]-CN-PMs, and the PTX release from rhApoE/PTX/A[beta]-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of A[beta]-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood-brain tumor barrier in vitro. Meanwhile, PTX/A[beta]-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/A[beta]-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona. Conclusions The designed PTX/A[beta]-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. Graphical Keywords: ApoE protein corona, Glioma, Targeting therapy, Paclitaxel The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle‒protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid β-protein (Aβ)-CN peptide (PTX/Aβ-CN-PMs). Aβ-CN peptide, like the Aβ1-42 peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding Aβ-CN-PMs (ApoE/PTX/Aβ-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood-brain barrier and glioma, effectively mediating brain-targeted delivery.BACKGROUNDThe interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle‒protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid β-protein (Aβ)-CN peptide (PTX/Aβ-CN-PMs). Aβ-CN peptide, like the Aβ1-42 peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding Aβ-CN-PMs (ApoE/PTX/Aβ-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood-brain barrier and glioma, effectively mediating brain-targeted delivery.PTX/Aβ-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC-MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/Aβ-CN-PMs were also well studied.METHODSPTX/Aβ-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC-MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/Aβ-CN-PMs were also well studied.The average size and zeta potential of PTX/Aβ-CN-PMs and ApoE/PTX/Aβ-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/Aβ-CN-PMs, and the PTX release from rhApoE/PTX/Aβ-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of Aβ-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood-brain tumor barrier in vitro. Meanwhile, PTX/Aβ-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/Aβ-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona.RESULTSThe average size and zeta potential of PTX/Aβ-CN-PMs and ApoE/PTX/Aβ-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/Aβ-CN-PMs, and the PTX release from rhApoE/PTX/Aβ-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of Aβ-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood-brain tumor barrier in vitro. Meanwhile, PTX/Aβ-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/Aβ-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona.The designed PTX/Aβ-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery.CONCLUSIONSThe designed PTX/Aβ-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. Abstract Background The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle‒protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid β-protein (Aβ)-CN peptide (PTX/Aβ-CN-PMs). Aβ-CN peptide, like the Aβ1–42 peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding Aβ-CN-PMs (ApoE/PTX/Aβ-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood–brain barrier and glioma, effectively mediating brain-targeted delivery. Methods PTX/Aβ-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC–MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/Aβ-CN-PMs were also well studied. Results The average size and zeta potential of PTX/Aβ-CN-PMs and ApoE/PTX/Aβ-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/Aβ-CN-PMs, and the PTX release from rhApoE/PTX/Aβ-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of Aβ-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood–brain tumor barrier in vitro. Meanwhile, PTX/Aβ-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/Aβ-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona. Conclusions The designed PTX/Aβ-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. Graphical Abstract The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle-protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid [beta]-protein (A[beta])-CN peptide (PTX/A[beta]-CN-PMs). A[beta]-CN peptide, like the A[beta].sub.1-42 peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding A[beta]-CN-PMs (ApoE/PTX/A[beta]-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood-brain barrier and glioma, effectively mediating brain-targeted delivery. PTX/A[beta]-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC-MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/A[beta]-CN-PMs were also well studied. The average size and zeta potential of PTX/A[beta]-CN-PMs and ApoE/PTX/A[beta]-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/A[beta]-CN-PMs, and the PTX release from rhApoE/PTX/A[beta]-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of A[beta]-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood-brain tumor barrier in vitro. Meanwhile, PTX/A[beta]-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/A[beta]-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona. The designed PTX/A[beta]-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. Background The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new biological properties to NPs and mediates their interactions with cells and biological barriers. Given the inevitable interactions, we regard nanoparticle‒protein interactions as a tool for designing protein corona-mediated drug delivery systems. Herein, we demonstrate the successful application of protein corona-mediated brain-targeted nanomicelles in the treatment of glioma, loading them with paclitaxel (PTX), and decorating them with amyloid β-protein (Aβ)-CN peptide (PTX/Aβ-CN-PMs). Aβ-CN peptide, like the Aβ1–42 peptide, specifically binds to the lipid-binding domain of apolipoprotein E (ApoE) in vivo to form the ApoE-enriched protein corona surrounding Aβ-CN-PMs (ApoE/PTX/Aβ-CN-PMs). The receptor-binding domain of the ApoE then combines with low-density lipoprotein receptor (LDLr) and LDLr-related protein 1 receptor (LRP1r) expressed in the blood–brain barrier and glioma, effectively mediating brain-targeted delivery. Methods PTX/Aβ-CN-PMs were prepared using a film hydration method with sonication, which was simple and feasible. The specific formation of the ApoE-enriched protein corona around nanoparticles was characterized by Western blotting analysis and LC–MS/MS. The in vitro physicochemical properties and in vivo anti-glioma effects of PTX/Aβ-CN-PMs were also well studied. Results The average size and zeta potential of PTX/Aβ-CN-PMs and ApoE/PTX/Aβ-CN-PMs were 103.1 nm, 172.3 nm, 7.23 mV, and 0.715 mV, respectively. PTX was efficiently loaded into PTX/Aβ-CN-PMs, and the PTX release from rhApoE/PTX/Aβ-CN-PMs exhibited a sustained-release pattern in vitro. The formation of the ApoE-enriched protein corona significantly improved the cellular uptake of Aβ-CN-PMs on C6 cells and human umbilical vein endothelial cells (HUVECs) and enhanced permeability to the blood–brain tumor barrier in vitro. Meanwhile, PTX/Aβ-CN-PMs with ApoE-enriched protein corona had a greater ability to inhibit cell proliferation and induce cell apoptosis than taxol. Importantly, PTX/Aβ-CN-PMs exhibited better anti-glioma effects and tissue distribution profile with rapid accumulation in glioma tissues in vivo and prolonged median survival of glioma-bearing mice compared to those associated with PMs without the ApoE protein corona. Conclusions The designed PTX/Aβ-CN-PMs exhibited significantly enhanced anti-glioma efficacy. Importantly, this study provided a strategy for the rational design of a protein corona-based brain-targeted drug delivery system. More crucially, we utilized the unfavorable side of the protein corona and converted it into an advantage to achieve brain-targeted drug delivery. |
| ArticleNumber | 453 |
| Audience | Academic |
| Author | Chen, Li-Qing Liu, Chao Zhang, Zhe-Ao Gao, Zhong-Gao Huang, Wei Liu, Yan-hong Qi, Ling-ling Xin, Xin Jin, Ming-Ji Duan, Hong-Xia Zhao, He-ming Zhang, Ying-Ying |
| Author_xml | – sequence: 1 givenname: Zhe-Ao orcidid: 0000-0002-5125-9915 surname: Zhang fullname: Zhang, Zhe-Ao – sequence: 2 givenname: Xin surname: Xin fullname: Xin, Xin – sequence: 3 givenname: Chao surname: Liu fullname: Liu, Chao – sequence: 4 givenname: Yan-hong surname: Liu fullname: Liu, Yan-hong – sequence: 5 givenname: Hong-Xia surname: Duan fullname: Duan, Hong-Xia – sequence: 6 givenname: Ling-ling surname: Qi fullname: Qi, Ling-ling – sequence: 7 givenname: Ying-Ying surname: Zhang fullname: Zhang, Ying-Ying – sequence: 8 givenname: He-ming surname: Zhao fullname: Zhao, He-ming – sequence: 9 givenname: Li-Qing surname: Chen fullname: Chen, Li-Qing – sequence: 10 givenname: Ming-Ji surname: Jin fullname: Jin, Ming-Ji – sequence: 11 givenname: Zhong-Gao surname: Gao fullname: Gao, Zhong-Gao – sequence: 12 givenname: Wei surname: Huang fullname: Huang, Wei |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34963449$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1r2zAUhs3oWD-2P7CLYdhNe-FO35ZvBqG0W6BssI9rIcvHjoIjZZISln8_uWlHUsZkhA7Hz3mNXr_nxYnzDoriLUbXGEvxIWLScFwhkjdGTV3JF8UZZnVdUcz5yUF9WpzHuESIEEbYq-KUskZQxpqzwn3xWxjLNmjrqqTDAAm60mnnV9bAOEIsex9K7ZKthtH6lS7TAoJe78oVdFZPdLubeuVs7W8rcMGaRW6ug09gXWl88E6XudrarX9dvOz1GOHN43lR_Ly7_XHzubr_-ml-M7uvDG_qVEndgO6FNtC2fY_rnlAhBRJgaF4tEUiSFmpDiCGSG0NAdo2UHW1qkFhqelHM97qd10u1Dnalw055bdVDw4dB6ZCsGUG1iHDZyZoB6xilRhogDLqm4xyRtq2z1se91nrT5jsbcCno8Uj0-I2zCzX4rZI15oLJLHD5KBD8rw3EpFY2TuZqB34TFRGYU0QaiTL6_hm69JvgslWZIhhRhukBNeh8Aet6n79rJlE1Ew0VvOZkoq7_QeWng_xvc5R6m_tHA1dHA5lJ8DsNehOjmn__dsy-OzTlrxtPycqA3AMm-BgD9MrYpJP1k0d2VBipKcRqH2KVQ6weQqwmv8iz0Sf1_wz9AdLl8sM |
| CitedBy_id | crossref_primary_10_1016_j_jddst_2024_105343 crossref_primary_10_1002_wnan_1982 crossref_primary_10_1016_j_bioadv_2025_214221 crossref_primary_10_7717_peerj_15571 crossref_primary_10_1016_j_jconrel_2023_06_014 crossref_primary_10_3390_biomimetics7030126 crossref_primary_10_1038_s41598_022_25737_7 crossref_primary_10_1021_acs_jafc_4c08452 crossref_primary_10_1039_D3NR01768K crossref_primary_10_1016_j_tips_2024_05_003 crossref_primary_10_1016_j_jconrel_2023_10_023 crossref_primary_10_1016_j_addr_2023_115114 crossref_primary_10_3389_fphar_2022_1051280 crossref_primary_10_1016_j_mtbio_2025_101457 crossref_primary_10_1021_acs_langmuir_4c00181 crossref_primary_10_3389_fnins_2023_1180943 crossref_primary_10_1016_j_ejps_2023_106468 crossref_primary_10_1016_j_ijbiomac_2023_128513 crossref_primary_10_1021_acsami_4c15045 crossref_primary_10_1002_smtd_202401860 crossref_primary_10_1021_acs_nanolett_4c04429 crossref_primary_10_1002_wnan_1853 crossref_primary_10_1016_j_addr_2022_114635 crossref_primary_10_1126_sciadv_adk9996 crossref_primary_10_1088_1361_6528_ad7b40 crossref_primary_10_1016_j_copbio_2023_103046 crossref_primary_10_1021_acs_molpharmaceut_4c01179 crossref_primary_10_1016_j_onano_2024_100215 crossref_primary_10_3390_pharmaceutics15082021 crossref_primary_10_1021_acschemneuro_3c00728 crossref_primary_10_3390_pharmaceutics15041176 crossref_primary_10_1016_j_ajps_2025_101021 crossref_primary_10_1002_advs_202308677 crossref_primary_10_1021_acsami_3c10364 |
| Cites_doi | 10.1021/acs.langmuir.0c01598 10.1016/S0021-9258(18)47945-8 10.1021/acsami.5b06429 10.1016/j.jconrel.2017.04.006 10.1016/j.jbiotec.2011.06.037 10.1016/j.biomaterials.2012.01.025 10.3389/fmicb.2020.01206 10.1021/acs.molpharmaceut.7b00341 10.1016/j.jconrel.2003.12.021 10.1038/s41467-018-06979-4 10.1073/pnas.1919755117 10.1021/acs.bioconjchem.6b00617 10.1371/journal.pone.0232565 10.1155/2017/8013575 10.1146/annurev.biochem.78.081307.110540 10.1016/0960-0760(92)90450-W 10.1016/j.jconrel.2018.04.035 10.1021/acsami.5b02803 10.1021/acsami.9b15910 10.1021/acs.molpharmaceut.8b00612 10.1089/nat.2019.0804 10.1021/acsami.8b11782 10.1016/j.jconrel.2015.09.059 10.1016/j.jconrel.2020.04.009 10.1016/j.ajps.2019.05.002 10.1021/acsnano.8b03500 10.1371/journal.pone.0135130 10.1016/j.jconrel.2019.06.033 10.1016/j.biopha.2017.05.125 10.2147/IJN.S303816 10.1111/boc.202000031 10.1016/j.colsurfb.2020.111527 10.1021/acsami.7b17927 10.1016/j.tibs.2006.06.008 10.1188/16.CJON.S1.2-8 10.1016/S0065-3233(08)60642-7 10.1038/mt.2009.281 10.1016/j.bpj.2020.07.035 10.1016/j.biomaterials.2014.01.071 10.1038/s41565-018-0171-6 10.1007/BF02482097 10.1021/acs.molpharmaceut.8b01344 10.1016/j.jconrel.2009.12.020 10.1021/acsami.7b06421 10.1039/C7SC00732A 10.1016/j.bioactmat.2021.04.027 10.1016/j.tibtech.2016.08.011 10.1021/bi702097s 10.3109/1061186X.2010.483517 10.1046/j.1471-4159.1999.0720230.x 10.1111/cas.14735 10.1021/acsami.5b04290 10.1021/ja010452r |
| ContentType | Journal Article |
| Copyright | 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION NPM ISR 3V. 7QO 7TB 7X7 7XB 88E 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AFKRA AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. KB. LK8 M0S M1P M7P P64 PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12951-021-01097-8 |
| DatabaseName | CrossRef PubMed Gale In Context: Science ProQuest Central (Corporate) Biotechnology Research Abstracts Mechanical & Transportation Engineering Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology Collection Natural Science Collection ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Mechanical & Transportation Engineering Abstracts ProQuest Central Essentials Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection Materials Science Database ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Materials Science Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1477-3155 |
| EndPage | 24 |
| ExternalDocumentID | oai_doaj_org_article_b0258d874e4d433c8ce24ed9d5502bb7 PMC8715648 A693657520 34963449 10_1186_s12951_021_01097_8 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 82073778 – fundername: State Key Laboratory of Bioactive Substance and Function of Natural Medicines grantid: GTZA201808 – fundername: Fundamental Research Funds for the Central Universities grantid: 3332021044 – fundername: ; grantid: 3332021044 – fundername: ; grantid: GTZA201808 – fundername: ; grantid: 82073778 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADDVE ADMLS ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D1I DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE I-F IAO IHR INH INR ISR ITC ITG ITH KB. KQ8 LK8 M1P M48 M7P MM. M~E O5R O5S OK1 OVT P2P PDBOC PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV RVI SCM SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 FRP NPM PMFND 7QO 7TB 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c597t-8a9eaf6acebbff17f2368606ec3333b26082be7c22c285cc2e8d988d397e818a3 |
| IEDL.DBID | DOA |
| ISSN | 1477-3155 |
| IngestDate | Wed Aug 27 01:25:15 EDT 2025 Thu Aug 21 13:31:16 EDT 2025 Mon Jul 21 11:35:10 EDT 2025 Fri Jul 25 09:07:39 EDT 2025 Tue Jun 17 21:05:41 EDT 2025 Tue Jun 10 20:36:30 EDT 2025 Fri Jun 27 04:19:54 EDT 2025 Wed Feb 19 02:27:24 EST 2025 Tue Jul 01 01:26:48 EDT 2025 Thu Apr 24 22:57:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Glioma ApoE protein corona Paclitaxel Targeting therapy |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c597t-8a9eaf6acebbff17f2368606ec3333b26082be7c22c285cc2e8d988d397e818a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5125-9915 |
| OpenAccessLink | https://doaj.org/article/b0258d874e4d433c8ce24ed9d5502bb7 |
| PMID | 34963449 |
| PQID | 2621034130 |
| PQPubID | 44676 |
| PageCount | 24 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b0258d874e4d433c8ce24ed9d5502bb7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8715648 proquest_miscellaneous_2615302980 proquest_journals_2621034130 gale_infotracmisc_A693657520 gale_infotracacademiconefile_A693657520 gale_incontextgauss_ISR_A693657520 pubmed_primary_34963449 crossref_citationtrail_10_1186_s12951_021_01097_8 crossref_primary_10_1186_s12951_021_01097_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-28 |
| PublicationDateYYYYMMDD | 2021-12-28 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of nanobiotechnology |
| PublicationTitleAlternate | J Nanobiotechnology |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Liang (1097_CR50) 2018; 10 M Zhang (1097_CR30) 2017; 28 L Tomar (1097_CR27) 2013; 8 X Wei (1097_CR49) 2015; 218 T Pillot (1097_CR25) 1999; 72 F Ahmed (1097_CR33) 2004; 96 M Tonigold (1097_CR35) 2018; 13 T Saito (1097_CR42) 2021; 112 Z Belhadj (1097_CR36) 2017; 255 A Suarez-Arnedo (1097_CR46) 2020; 15 I Jung-Testas (1097_CR56) 1992; 42 KH Weisgraber (1097_CR20) 1994; 45 H Zuo (1097_CR9) 2017; 9 S Varadarajan (1097_CR23) 2001; 123 X Cheng (1097_CR18) 2015; 7 Z Li (1097_CR19) 2020; 15 RE Pitas (1097_CR55) 1987; 262 K Shi (1097_CR6) 2015; 7 MA Rajora (1097_CR53) 2017; 8 M Yamamoto (1097_CR52) 1998; 15 G Su (1097_CR17) 2018; 15 H Dong (1097_CR28) 2015; 7 JY Oh (1097_CR12) 2018; 9 R Cai (1097_CR16) 2020; 12 C Zhan (1097_CR34) 2010; 143 G Biddeci (1097_CR43) 2021; 16 S Lakkadwala (1097_CR47) 2019; 307 Y Fan (1097_CR29) 2021; 6 JM Shi (1097_CR45) 2020; 119 Z Ban (1097_CR14) 2020; 117 D Vercauteren (1097_CR38) 2010; 18 L Maletínská (1097_CR54) 2000; 60 Q Yu (1097_CR39) 2020; 11 Z Chen (1097_CR2) 2017; 14 J Aparicio-Blanco (1097_CR8) 2019; 16 K Anjum (1097_CR1) 2017; 92 S Tamamizu-Kato (1097_CR24) 2008; 47 A Cox (1097_CR13) 2018; 12 G Caracciolo (1097_CR11) 2017; 35 H Kim (1097_CR15) 2021; 199 J Shen (1097_CR32) 2011; 19 D Vocelle (1097_CR37) 2020; 30 I Foissner (1097_CR41) 2020; 112 J Li (1097_CR7) 2020; 322 W Szopa (1097_CR4) 2017; 2017 J Ren (1097_CR31) 2012; 33 F Re (1097_CR26) 2011; 156 SH Kim (1097_CR51) 2015; 10 Z Ji (1097_CR44) 2020; 36 H Ruan (1097_CR3) 2018; 279 N Hartl (1097_CR21) 2021; 4 T Tian (1097_CR10) 2018; 10 B Zhang (1097_CR48) 2014; 35 ME Davis (1097_CR5) 2016; 20 DM Hatters (1097_CR22) 2006; 31 GJ Doherty (1097_CR40) 2009; 78 |
| References_xml | – volume: 36 start-page: 8632 issue: 29 year: 2020 ident: 1097_CR44 publication-title: Langmuir doi: 10.1021/acs.langmuir.0c01598 – volume: 262 start-page: 14352 issue: 29 year: 1987 ident: 1097_CR55 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)47945-8 – volume: 7 start-page: 21442 issue: 38 year: 2015 ident: 1097_CR6 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.5b06429 – volume: 255 start-page: 132 year: 2017 ident: 1097_CR36 publication-title: J Control Release doi: 10.1016/j.jconrel.2017.04.006 – volume: 156 start-page: 341 issue: 4 year: 2011 ident: 1097_CR26 publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2011.06.037 – volume: 33 start-page: 3324 issue: 11 year: 2012 ident: 1097_CR31 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2012.01.025 – volume: 11 start-page: 1206 year: 2020 ident: 1097_CR39 publication-title: Front Microbiol doi: 10.3389/fmicb.2020.01206 – volume: 14 start-page: 3087 issue: 9 year: 2017 ident: 1097_CR2 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.7b00341 – volume: 4 start-page: 1 year: 2021 ident: 1097_CR21 publication-title: Adv Ther (Weinh). – volume: 8 start-page: 505 year: 2013 ident: 1097_CR27 publication-title: Int J Nanomed – volume: 96 start-page: 37 issue: 1 year: 2004 ident: 1097_CR33 publication-title: J Control Release doi: 10.1016/j.jconrel.2003.12.021 – volume: 9 start-page: 4548 issue: 1 year: 2018 ident: 1097_CR12 publication-title: Nat Commun doi: 10.1038/s41467-018-06979-4 – volume: 117 start-page: 10492 issue: 19 year: 2020 ident: 1097_CR14 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1919755117 – volume: 28 start-page: 775 issue: 3 year: 2017 ident: 1097_CR30 publication-title: Bioconjug Chem doi: 10.1021/acs.bioconjchem.6b00617 – volume: 15 start-page: e232565 issue: 7 year: 2020 ident: 1097_CR46 publication-title: PLoS ONE doi: 10.1371/journal.pone.0232565 – volume: 2017 start-page: 8013575 year: 2017 ident: 1097_CR4 publication-title: Biomed Res Int doi: 10.1155/2017/8013575 – volume: 78 start-page: 857 year: 2009 ident: 1097_CR40 publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.78.081307.110540 – volume: 42 start-page: 597 issue: 6 year: 1992 ident: 1097_CR56 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/0960-0760(92)90450-W – volume: 279 start-page: 306 year: 2018 ident: 1097_CR3 publication-title: J Control Release doi: 10.1016/j.jconrel.2018.04.035 – volume: 7 start-page: 11015 issue: 20 year: 2015 ident: 1097_CR28 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.5b02803 – volume: 12 start-page: 1997 issue: 2 year: 2020 ident: 1097_CR16 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.9b15910 – volume: 15 start-page: 5019 issue: 11 year: 2018 ident: 1097_CR17 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.8b00612 – volume: 60 start-page: 2300 issue: 8 year: 2000 ident: 1097_CR54 publication-title: Cancer Res – volume: 30 start-page: 22 issue: 1 year: 2020 ident: 1097_CR37 publication-title: Nucleic Acid Ther doi: 10.1089/nat.2019.0804 – volume: 10 start-page: 30201 issue: 36 year: 2018 ident: 1097_CR50 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.8b11782 – volume: 218 start-page: 13 year: 2015 ident: 1097_CR49 publication-title: J Control Release doi: 10.1016/j.jconrel.2015.09.059 – volume: 322 start-page: 542 year: 2020 ident: 1097_CR7 publication-title: J Control Release doi: 10.1016/j.jconrel.2020.04.009 – volume: 15 start-page: 482 issue: 4 year: 2020 ident: 1097_CR19 publication-title: Asian J Pharm Sci doi: 10.1016/j.ajps.2019.05.002 – volume: 12 start-page: 7292 issue: 7 year: 2018 ident: 1097_CR13 publication-title: ACS Nano doi: 10.1021/acsnano.8b03500 – volume: 10 start-page: e0135130 issue: 8 year: 2015 ident: 1097_CR51 publication-title: PLoS ONE doi: 10.1371/journal.pone.0135130 – volume: 307 start-page: 247 year: 2019 ident: 1097_CR47 publication-title: J Control Release doi: 10.1016/j.jconrel.2019.06.033 – volume: 92 start-page: 681 year: 2017 ident: 1097_CR1 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2017.05.125 – volume: 16 start-page: 4755 year: 2021 ident: 1097_CR43 publication-title: Int J Nanomedicine doi: 10.2147/IJN.S303816 – volume: 112 start-page: 317 issue: 11 year: 2020 ident: 1097_CR41 publication-title: Biol Cell doi: 10.1111/boc.202000031 – volume: 199 start-page: 111527 year: 2021 ident: 1097_CR15 publication-title: Colloids Surf B Biointerfaces doi: 10.1016/j.colsurfb.2020.111527 – volume: 10 start-page: 3414 issue: 4 year: 2018 ident: 1097_CR10 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.7b17927 – volume: 31 start-page: 445 issue: 8 year: 2006 ident: 1097_CR22 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2006.06.008 – volume: 20 start-page: S2 issue: 5 Suppl year: 2016 ident: 1097_CR5 publication-title: Clin J Oncol Nurs doi: 10.1188/16.CJON.S1.2-8 – volume: 45 start-page: 249 year: 1994 ident: 1097_CR20 publication-title: Adv Protein Chem doi: 10.1016/S0065-3233(08)60642-7 – volume: 18 start-page: 561 issue: 3 year: 2010 ident: 1097_CR38 publication-title: Mol Ther doi: 10.1038/mt.2009.281 – volume: 119 start-page: 1078 issue: 6 year: 2020 ident: 1097_CR45 publication-title: Biophys J doi: 10.1016/j.bpj.2020.07.035 – volume: 35 start-page: 4133 issue: 13 year: 2014 ident: 1097_CR48 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2014.01.071 – volume: 13 start-page: 862 issue: 9 year: 2018 ident: 1097_CR35 publication-title: Nat Nanotechnol doi: 10.1038/s41565-018-0171-6 – volume: 15 start-page: 23 issue: 1 year: 1998 ident: 1097_CR52 publication-title: Brain Tumor Pathol doi: 10.1007/BF02482097 – volume: 16 start-page: 1999 issue: 5 year: 2019 ident: 1097_CR8 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.8b01344 – volume: 143 start-page: 136 issue: 1 year: 2010 ident: 1097_CR34 publication-title: J Control Release doi: 10.1016/j.jconrel.2009.12.020 – volume: 9 start-page: 20444 issue: 24 year: 2017 ident: 1097_CR9 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.7b06421 – volume: 8 start-page: 5371 issue: 8 year: 2017 ident: 1097_CR53 publication-title: Chem Sci doi: 10.1039/C7SC00732A – volume: 6 start-page: 4402 issue: 12 year: 2021 ident: 1097_CR29 publication-title: Bioact Mater doi: 10.1016/j.bioactmat.2021.04.027 – volume: 35 start-page: 257 issue: 3 year: 2017 ident: 1097_CR11 publication-title: Trends Biotechnol doi: 10.1016/j.tibtech.2016.08.011 – volume: 47 start-page: 5225 issue: 18 year: 2008 ident: 1097_CR24 publication-title: Biochemistry-Us doi: 10.1021/bi702097s – volume: 19 start-page: 197 issue: 3 year: 2011 ident: 1097_CR32 publication-title: J Drug Target doi: 10.3109/1061186X.2010.483517 – volume: 72 start-page: 230 issue: 1 year: 1999 ident: 1097_CR25 publication-title: J Neurochem doi: 10.1046/j.1471-4159.1999.0720230.x – volume: 112 start-page: 550 issue: 2 year: 2021 ident: 1097_CR42 publication-title: Cancer Sci doi: 10.1111/cas.14735 – volume: 7 start-page: 20568 issue: 37 year: 2015 ident: 1097_CR18 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.5b04290 – volume: 123 start-page: 5625 issue: 24 year: 2001 ident: 1097_CR23 publication-title: J Am Chem Soc doi: 10.1021/ja010452r |
| SSID | ssj0022424 |
| Score | 2.469767 |
| Snippet | The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which provides new... Background The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological environment, which... Abstract Background The interactions between nanoparticles (NPs) and plasma proteins form a protein corona around NPs after entering the biological... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 453 |
| SubjectTerms | Analysis ApoE protein corona Apolipoprotein E Apolipoproteins Apoptosis Binding Binding sites Bioaccumulation Biological properties Blood-brain barrier Brain cancer Brain tumors Care and treatment Cell proliferation Controlled release Diagnosis Dosage and administration Drug delivery Drug delivery systems Drug development Drugs Efficiency Endothelial cells Enrichment Glioma Gliomas Health aspects Lipids Low density lipoprotein receptors Methods Nanoparticles NMR Nuclear magnetic resonance Paclitaxel Peptides Permeability Physicochemical properties Plasma proteins Protein interaction Proteins Receptor density Receptors Risk factors Sonication Targeting therapy Tumors Umbilical vein Vehicles Western blotting Zeta potential β-Amyloid |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXOCAeBMoyCAkDshq4ySOfUILalWQ6AGotDfLr2xXWpKl2V2p_54Zx7vdCKk5RfEkSjzjsT9n5htCPghhuXW8YrKqOSulk8zUTcOUdaUyviyCxNzhH-fi7KL8Pq2macOtT2GVW58YHbXvHO6RH3EB4CS63M_LvwyrRuHf1VRC4y65h9RlGNJVT28AF6Y-bBNlpDjqYW6rADxzBNDHCrzzaDKKnP3_e-a9qWkcNrk3D50-Ig_TApJOBo0_JndC-4Q82KMVfEra824TFtRi9Qc2hHoHT1sTM5Bxo76nsFSl0KdzNlvMuz-GDmlY1zQmkqC0vcZrdLLsThiYGAaMehpJHeYtdUh7YCicbeab7hm5OD35_fWMpboKzAF8WDFpVDCNMC5Y2zR53fBCSAAywRVwWEA4kttQO84dl5VzPEivpPSwdAkwv5viOTlouza8JFQIpayvlS8KB3qF51VBwKMNIO4coExG8m0Ha5dIx7H2xUJH8CGFHpSiQSk6KkXLjHza3bMcKDdulf6CettJIl12vNBdzXQafdrCyk56WZehBPMrnHSBl8ErD_iMW1tn5D1qXSMhRosRNzOz7nv97ddPPRGqwJ9T_DgjH5NQ08E3OJMSGKAnkENrJHk4koQR68bNW-PSyWP0-sa-M_Ju14x3YhRcG7o1yuRY5ElJkHkx2OLuu5H4vyhLlZF6ZKWjjhm3tPPLyCcOmLkSpXx1-2u9Jvc5Dp0c0_kPycHqah3ewIJsZd_GUfcP_g40Zw priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZKucAB8SZtQQYhcUCBxnEc-4DQgloVpPYArNSbZTvONtKSlH2J_ffMOA9tRMWJPa3iSaTMIzNf4vmGkNdCWGYdy2KZ5Szm0snY5GUZK-u4MgVPvcTe4fMLcTblXy-zyz3SjzvqFLi8EdrhPKnpYv7u96_tRwj4DyHgpXi_hJyVAShmCIyPFTx1b5HbkJlyDNRzPnxVYNgK0TfO3HjeKDkFDv-_n9Q7qWq8jXInL53eJ_e6gpJOWg94QPZ8_ZDc3aEZfETqi2bj59TiNIi43frtC1qb0JGML-6XFEpXCjqu4tm8an4a2rZlbWloLEFpu8VjdHLdnMTgcriBtKCB5KGqqUMaBEPh36baNI_J9PTkx-ezuJuzEDuAE6tYGuVNKYzz1pZlkpcsFRKAjXcp_CwgHsmszx1jjsnMOeZloaQsoJTxkO9N-oTs103tnxEqhFK2yFWRpg7sDNfLvIBLG0DgCUCbiCS9grXrSMhxFsZcBzAihW6NosEoOhhFy4i8Hc65bik4_in9Ce02SCJ9djjQLGa6i0ZtodKThcy55-COqZPOM-4LVQBeY9bmEXmFVtdIkFHjDpyZWS-X-sv3b3oiVIofq9hxRN50QmUD9-BM19AAmkBOrZHk0UgSItiNl3vn0n0AaCYAjIcSIyIvh2U8E3fF1b5Zo0yCQ5-UBJmnrS8O942DAFLOVUTykZeOFDNeqaurwC8OGDoTXB78D00ekjsMAyxBEoAjsr9arP1zKONW9kWIzT8_HUTI priority: 102 providerName: Scholars Portal |
| Title | Novel brain-targeted nanomicelles for anti-glioma therapy mediated by the ApoE-enriched protein corona in vivo |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34963449 https://www.proquest.com/docview/2621034130 https://www.proquest.com/docview/2615302980 https://pubmed.ncbi.nlm.nih.gov/PMC8715648 https://doaj.org/article/b0258d874e4d433c8ce24ed9d5502bb7 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgvMAD4puMURmExAOKtjqOc37sUMtAWoUGk_pm2Y6zVSrJRD-k_fe7c9KqERK80Ieoii9Rc3f23S-9-5mxD0o54bzIU8gLkUrwkNqiqlLtvNS2lFkA6h0-n6qzS_ltls_2tvqimrCWHrhV3LHDoAwlFDJIvDLz4IOQodQlptbCudhHjjFvC6Y6qEVND9sWGVDHS4xqOcJmQdD5ROO63AtDka3_zzV5Lyj1Cyb3ItDkCXvcpY581P7kp-xeqJ-xR3uEgs9ZPW02YcEd7fuQtkXeoeS1jb3H9Ip-yTFJ5ajNeXq1mDe_LG8bsG55bCEhaXdL5_jophmn6FxUKlrySOcwr7knwgPL8dtmvmlesMvJ-Ofns7TbUSH1CBxWKVgdbKWsD85V1bCoRKYAIUzwGX4cYhsQLhReCC8g914EKDVAiUlLwMhus5fsoG7q8JpxpbR2ZaFLtAlaFO-XB4W3toi1hwhiEjbcKtj4jm6cdr1YmAg7QJnWKAaNYqJRDCTs0-6am5Zs46_Sp2S3nSQRZccT6D6mcx_zL_dJ2HuyuiEqjJpqba7serk0X39cmJHSGf0tJU4S9rETqhp8Bm-71gXUBLFn9SSPepI4V31_eOtcplsrlkYohN0xmUjYu90wXUn1b3Vo1iQzpO2dNKDMq9YXd89NlP-ZlDphRc9Le4rpj9Tz68gkjmg5VxIO_4cm37CHgibYkNr9j9jB6vc6vMWEbeUG7H4xK_AIky8D9uB0PP1-MYjzFY_nEu4A59RBaw |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGeAAeEN8EBhgE4gFFa5zEsR8QKrCpZVsfYJP65tmOUyqVpCxtUf8p_kbu8tE1Qtrb8hTFF6vx3fnuV98HIW85N8xYFvsiTpgfCSt8nWSZL42NpE6j0AnMHT4Z8cFZ9G0cj3fI3zYXBsMq2z2x2qjTwuJ_5PuMAzipttxP898-do3C09W2hUYtFkdu_QcgW_lx-BX4-46xw4PTLwO_6SrgW3CeF77Q0umMa-uMybIgyVjIBbjxzoZwGfDvBTMusYxZJmJrmROpFCIFw-3AuukQ5r1BboLh7aFGJeNLgIepFm1ijuD7JdjSGMA6Q8Dek2ANOsav6hHwvyXYMoXdMM0tu3d4j9xtHFbaryXsPtlx-QNyZ6uM4UOSj4qVm1GD3Sb8OrTcpTTXVcYzHgyUFFxjCjyc-pPZtPilaZ32taZV4gpSmzU-o_15ceCDSGOAakqrIhLTnFoss6Ap3K2mq-IRObuWFX9MdvMid08J5VxKkyYyDUMLcgTzxY7D1BoQfgDQySNBu8DKNkXOsdfGTFVgR3BVM0UBU1TFFCU88mHzzrwu8XEl9Wfk24YSy3NXD4qLiWq0XRnwJEUqkshFIO6hFdaxyKUyBTzIjEk88ga5rrAAR44RPhO9LEs1_PFd9bkM8TCM9TzyviHKCvgGq5uECVgJrNnVodzrUMIOYbvDrXCpZocq1aU-eeT1ZhjfxKi73BVLpAmwqZQUQPOklsXNd2OjgTCKpEeSjpR2FqY7kk9_VvXLAaPHPBLPrv5Zr8itwenJsToejo6ek9sM1SjAUgJ7ZHdxsXQvwBlcmJeVBlJyft0q_w8fWXIA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+brain-targeted+nanomicelles+for+anti-glioma+therapy+mediated+by+the+ApoE-enriched+protein+corona+in+vivo&rft.jtitle=Journal+of+nanobiotechnology&rft.au=Zhe-Ao+Zhang&rft.au=Xin+Xin&rft.au=Chao+Liu&rft.au=Yan-hong+Liu&rft.date=2021-12-28&rft.pub=BMC&rft.eissn=1477-3155&rft.volume=19&rft.issue=1&rft.spage=1&rft.epage=24&rft_id=info:doi/10.1186%2Fs12951-021-01097-8&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b0258d874e4d433c8ce24ed9d5502bb7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-3155&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-3155&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-3155&client=summon |